

Title (en)

OLIGONUCLEOTIDES FOR MODULATING APOLIPOPROTEIN E4 EXPRESSION

Title (de)

OLIGONUKLEOTIDE ZUR MODULATION DER APOLIPOPROTEIN E4-EXPRESSION

Title (fr)

OLIGONUCLÉOTIDES POUR MODULER L'EXPRESSION DE L'APOLIPOPROTÉINE E4

Publication

EP 4426833 A1 20240911 (EN)

Application

EP 22817100 A 20221102

Priority

- EP 21206278 A 20211103
- EP 2022080478 W 20221102

Abstract (en)

[origin: WO2023078883A1] The present invention relates to antisense oligonucleotides that are capable of modulating expression of Apolipoprotein E4 (ApoE4) in a target cell. The oligonucleotides can hybridize to APOE ε4 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of, for example, Alzheimer's disease (AD), fronto-temporal dementia (FTD), Pick's disease (PiD), progressive supranuclear palsy (PSP), movement disorders such as Parkinson's disease (PD), dementia with Lewy Bodies, dementia in Down's Syndrome, and Niemann-Pick Type C1 Disease.

IPC 8 full level

C12N 15/113 (2010.01); **A61K 31/712** (2006.01); **A61P 25/28** (2006.01)

CPC (source: EP US)

A61K 31/712 (2013.01 - EP); **C12N 15/113** (2013.01 - EP US); **C12N 2310/11** (2013.01 - EP US); **C12N 2310/315** (2013.01 - US);
C12N 2310/3231 (2013.01 - EP US); **C12N 2310/3341** (2013.01 - US); **C12N 2310/341** (2013.01 - EP); **C12N 2310/343** (2013.01 - EP);
C12N 2310/344 (2013.01 - EP); **C12N 2310/351** (2013.01 - US); **C12N 2320/34** (2013.01 - EP)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2023078883 A1 20230511; CN 118318042 A 20240709; EP 4426833 A1 20240911; US 2024294915 A1 20240905

DOCDB simple family (application)

EP 2022080478 W 20221102; CN 202280073646 A 20221102; EP 22817100 A 20221102; US 202418652148 A 20240501